




PHARMACEUTICAL 2023

Decibel Therapeutics Inc.
Rank 220 of 446





RealRate

PHARMACEUTICAL 2023

Decibel Therapeutics Inc. Rank 220 of 446



The relative strengths and weaknesses of Decibel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Decibel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Decibel Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 51% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	108,030
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,442
Liabilities, Non-Current	12,373
Other Assets	10,817
Other Compr. Net Income	-91
Other Expenses	240
Other Liabilities	6,765
Other Net Income	1,192
Other Revenues	0
Property and Equipment	4,526
Research and Development	40,330
Selling, General and Administrative Expense	23,627

Output Variable	Value in 1000 USD
Assets	123,373
Liabilities	41,580
Expenses	64,197
Revenues	0
Stockholders Equity	81,793
Net Income	-63,005
Comprehensive Net Income	-63,050
Economic Capital Ratio	94%